ATE442376T1 - Oligonukleotide mit einer immunsystemstimulierenden sequenz und verfahren zu deren anwendung - Google Patents

Oligonukleotide mit einer immunsystemstimulierenden sequenz und verfahren zu deren anwendung

Info

Publication number: ATE442376T1
Authority: AT; Austria
Prior art keywords: oligonucleotides; immune system; stimulating sequence; stimulating; sequence
Prior art date: 2002-12-23

Application number

AT03814325T

Other languages

English (en)

Inventor

Dino Dina

Karen Fearon

Jason Marshall

Original Assignee

Dynavax Tech Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-23

Filing date

2003-12-18

Publication date

2009-09-15

2003-12-18 Application filed by Dynavax Tech Corp filed Critical Dynavax Tech Corp

2009-09-15 Application granted granted Critical

2009-09-15 Publication of ATE442376T1 publication Critical patent/ATE442376T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
230000002519 immonomodulatory effect Effects 0.000 abstract 3
102000040430 polynucleotide Human genes 0.000 abstract 2
108091033319 polynucleotide Proteins 0.000 abstract 2
239000002157 polynucleotide Substances 0.000 abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
- A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Pulmonology (AREA)
General Engineering & Computer Science (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Dermatology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Toxicology (AREA)
Tropical Medicine & Parasitology (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Otolaryngology (AREA)
Agronomy & Crop Science (AREA)
Pest Control & Pesticides (AREA)
Dentistry (AREA)
Environmental Sciences (AREA)

AT03814325T 2002-12-23 2003-12-18 Oligonukleotide mit einer immunsystemstimulierenden sequenz und verfahren zu deren anwendung ATE442376T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US43612202P	2002-12-23	2002-12-23
US44788503P	2003-02-13	2003-02-13
US46754603P	2003-05-01	2003-05-01
PCT/US2003/041001 WO2004058179A2 (en)	2002-12-23	2003-12-18	Immunostimulatory sequence oligonucleotides and methods of using the same

Publications (1)

Publication Number	Publication Date
ATE442376T1 true ATE442376T1 (de)	2009-09-15

Family

ID=32686090

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT08013086T ATE544772T1 (de)	2002-12-23	2003-12-18	Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür
AT03814325T ATE442376T1 (de)	2002-12-23	2003-12-18	Oligonukleotide mit einer immunsystemstimulierenden sequenz und verfahren zu deren anwendung

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT08013086T ATE544772T1 (de)	2002-12-23	2003-12-18	Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür

Country Status (17)

Country	Link
US (1)	US7745606B2 (de)
EP (2)	EP1992635B1 (de)
JP (2)	JP5102959B2 (de)
KR (3)	KR101309501B1 (de)
CN (2)	CN100546998C (de)
AT (2)	ATE544772T1 (de)
AU (1)	AU2003297483B2 (de)
CA (1)	CA2511475C (de)
CY (2)	CY1109642T1 (de)
DE (1)	DE60329223D1 (de)
DK (2)	DK1992635T3 (de)
ES (2)	ES2381309T3 (de)
NZ (1)	NZ541027A (de)
PT (2)	PT1992635E (de)
SG (2)	SG2011035342A (de)
SI (1)	SI1575977T1 (de)
WO (1)	WO2004058179A2 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030129251A1 (en) *	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
KR100917101B1 (ko) *	2000-08-04	2009-09-15	도요 보세키 가부시키가이샤	플렉시블 금속적층체 및 그 제조방법
KR100985457B1 (ko) *	2001-06-21	2010-10-06	다이나박스 테크놀로지 코퍼레이션	키메라 면역조절 화합물 및 그것들의 사용 방법
EA007232B1 (ru) *	2001-08-17	2006-08-25	Коли Фармасьютикал Гмбх	Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
US7884083B2 (en) *	2002-08-12	2011-02-08	Dynavax Technologies Corporation	Immunomodulatory compositions, methods of making, and methods of use thereof
US7956043B2 (en) *	2002-12-11	2011-06-07	Coley Pharmaceutical Group, Inc.	5′ CpG nucleic acids and methods of use
DK1992635T3 (da)	2002-12-23	2012-03-05	Dynavax Tech Corp	Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
US8158768B2 (en)	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
PL1794174T3 (pl) *	2004-09-01	2012-11-30	Dynavax Tech Corp	Sposoby i kompozycje do hamowania wrodzonych odpowiedzi immunologicznych i autoodporności
US8072945B2 (en)	2004-09-24	2011-12-06	Aes Corporation	Link layered networks
JP2008000001A (ja) *	2004-09-30	2008-01-10	Osaka Univ	免疫刺激オリゴヌクレオチドおよびその医薬用途
MY159370A (en) *	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
JP4836145B2 (ja) *	2005-01-28	2011-12-14	クウォン，ヒュン−ジョ	マイコバクテリアに由来する、免疫機能刺激用、免疫疾患治療用、アトピー性皮膚炎治療用および／または正常免疫細胞保護用オリゴヌクレオチド
KR20070110901A (ko)	2005-03-04	2007-11-20	다이나박스 테크놀로지 코퍼레이션	항원에 콘쥬게이트되고 버퍼 조건 및 추가의 부형제들에의해 안정화된 면역자극성 서열(ｉｓｓ)을 갖는올리고뉴클레오티드를 포함하는 백신
EP1874325A2 (de) *	2005-04-08	2008-01-09	Coley Pharmaceutical Group, Inc.	Verfahren zur behandlung von durch infektionserkrankungen verschlimmertes asthma
SI2380584T1 (sl)	2005-07-01	2014-04-30	Index Pharmaceuticals Ab	Imunostimulatorni postopek
PT2179737E (pt)	2005-07-01	2013-12-05	Index Pharmaceuticals Ab	Método para modular a capacidade de resposta aos esteróides
CA2523032A1 (en)	2005-10-07	2007-04-07	Immunovaccine Technologies Inc.	Vaccines for cancer therapy
AU2006306805A1 (en)	2005-10-28	2007-05-03	Index Pharmaceuticals Ab	Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
EP2005161B1 (de) *	2006-03-17	2016-02-24	NewSouth Innovations Pty Limited	Elektrochemischer sensor
DK2034015T3 (da)	2006-05-31	2012-10-15	Toray Industries	Immunstimulerende oligonucleotid og farmaceutisk anvendelse heraf
WO2008073661A2 (en)	2006-11-09	2008-06-19	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
CA2693266C (en) *	2007-08-01	2015-06-30	Idera Pharmaceuticals, Inc.	Novel synthetic agonists of tlr9
US20090196915A1 (en) *	2007-08-21	2009-08-06	Gary Van Nest	Composition and methods of making and using influenza proteins
ES2588705T3 (es)	2007-09-27	2016-11-04	Immunovaccine Technologies Inc.	Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
EP2209896B1 (de)	2007-10-26	2017-03-01	Dynavax Technologies Corporation	Verfahren und zusammensetzungen zur hemmung von immunantworten und autoimmunität
AU2009246169B2 (en)	2008-05-15	2015-01-22	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
CA2723918C (en)	2008-06-05	2018-01-09	Immunovaccine Technologies Inc.	Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
WO2010108140A1 (en) *	2009-03-20	2010-09-23	Alios Biopharma, Inc.	Substituted nucleoside and nucleotide analogs
US8981044B2 (en)	2010-04-21	2015-03-17	National University Corporation Hokkaido University	Lipid membrane structure having intranuclear migrating property
CN107029223A (zh)	2010-05-26	2017-08-11	西莱克塔生物科技公司	合成纳米载体联合疫苗
CN103153346A (zh)	2010-06-16	2013-06-12	戴纳瓦克斯技术公司	使用tlr7和/或tlr9抑制剂的治疗方法
WO2012040127A1 (en)	2010-09-22	2012-03-29	Alios Biopharma, Inc.	Substituted nucleotide analogs
EP2640190A4 (de)	2010-11-05	2016-05-11	Selecta Biosciences Inc	Modifizierte nikotinische verbindungen und zugehörige verfahren
DK2640426T3 (en) *	2010-11-16	2016-05-02	Selecta Biosciences Inc	Immunostimulating Oligonucleotides
EP2471926A3 (de) *	2010-12-30	2012-07-11	Intervet International BV	Immunstimulierende Oligodeoxynukleotide
KR102190180B1 (ko) *	2011-04-15	2020-12-11	고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸	Ｄｎａ 백신
US9315814B2 (en) *	2011-05-26	2016-04-19	Intervet Inc.	Immunostimulatory oligodeoxynucleotides
JP5872684B2 (ja) *	2011-05-26	2016-03-01	インターベットインターナショナルベー．フェー．	免疫刺激性オリゴデオキシヌクレオチド
JP2014521687A (ja)	2011-07-29	2014-08-28	セレクタバイオサイエンシーズインコーポレーテッド	体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
IN2014CN02581A (de)	2011-10-06	2015-08-07	Immunovaccine Technologies Inc
EP2794630A4 (de)	2011-12-22	2015-04-01	Alios Biopharma Inc	Substituierte phosphorthioat-nukleotidanaloga
NZ631601A (en)	2012-03-21	2016-06-24	Alios Biopharma Inc	Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en)	2012-03-22	2016-01-29	Alios Biopharma Inc	Pharmaceutical combinations comprising a thionucleotide analog
CN102719436A (zh) *	2012-06-27	2012-10-10	南开大学	一种寡核苷酸及其制备在防治心肌肥大与心力衰竭药物中的用途
JP6001974B2 (ja)	2012-09-21	2016-10-05	アンジェスＭｇ株式会社	アポリポプロテイン（ａ）の特異的エピトープを含むＤＮＡワクチン
AU2015269412B2 (en)	2014-06-04	2020-03-12	Exicure Operating Company	Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016081911A2 (en)	2014-11-21	2016-05-26	Northwestern University	The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3238727B1 (de) *	2014-12-25	2023-01-18	National Institutes of Biomedical Innovation, Health and Nutrition	Nichtaggregierende immunstimulierende oligonukleotide
MX2017015311A (es) *	2015-05-29	2018-06-19	Merck Sharp & Dohme	Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.
EP3302501B1 (de) *	2015-05-29	2021-09-22	Merck Sharp & Dohme Corp.	Kombination aus einem pd-1-antagonisten und cpg-c-typ-oligonukleotid zur behandlung von krebs
KR102779525B1 (ko) *	2015-05-29	2025-03-12	다이나박스 테크놀로지 코퍼레이션	폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여
CN106256905B (zh) *	2015-11-24	2019-08-13	华中农业大学	一种对草鱼有免疫增强活性的CpG ODN序列及其应用
CN105567782B (zh) *	2016-01-29	2020-08-04	山东省农业科学院畜牧兽医研究所	鸡胚成纤维细胞在体外筛选CpG寡聚脱氧核苷酸活性分子中的应用
CA3020873A1 (en) *	2016-04-15	2017-10-19	Dynavax Technologies Corporation	Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
WO2018039629A2 (en)	2016-08-25	2018-03-01	Northwestern University	Micellar spherical nucleic acids from thermoresponsive, traceless templates
US10463686B2 (en) *	2016-09-15	2019-11-05	Idera Pharmaceuticals, Inc.	Immune modulation with TLR9 agonists for cancer treatment
WO2018209270A1 (en)	2017-05-11	2018-11-15	Northwestern University	Adoptive cell therapy using spherical nucleic acids (snas)
GB201718701D0 (en) *	2017-11-13	2017-12-27	Syngenta Participations Ag	Improvements in or relating to gene silencing
TW202011959A (zh)	2018-04-14	2020-04-01	美商戴納瓦克斯技術公司	用於治療癌症之包括CpG-C 型寡核苷酸及組蛋白去乙醯酶抑制劑之組合
WO2020081398A1 (en)	2018-10-14	2020-04-23	Dynavax Technologies Corporation	Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer
EP3966331A4 (de) *	2019-05-10	2023-07-05	Microbio (Shanghai) Co., Ltd.	Dimere cpg-oligonukleotide zur verwendung bei der modulation von immunantworten
CN113058033B (zh) *	2019-12-16	2024-07-09	远大赛威信生命科学(南京)有限公司	一种用于预防和治疗乙型肝炎的药物组合物及其用途
US11613755B2 (en)	2019-12-31	2023-03-28	Industrial Technology Research Institute	Nucleic acid-drug complex and use thereof
US20230092650A1 (en) *	2020-03-01	2023-03-23	Dynavax Technologies Corporation	Coronavirus vaccines comprising a tlr9 agonist
MX2022010642A (es) *	2020-03-01	2022-11-08	Dynavax Tech Corp	Vacunas contra coronavirus que comprenden un agonista de tlr9.
WO2021178306A1 (en) *	2020-03-01	2021-09-10	Dynavax Technologies Corporation	Coronavirus vaccines comprising a tlr9 agonist
US20250009731A1 (en)	2021-11-08	2025-01-09	Nurix Therapeutics, Inc.	Toll-like receptor therapy combinations with cbl-b inhibitor compounds
AU2024272997A1 (en) *	2023-05-16	2025-11-27	The Board Of Trustees Of The Leland Stanford Junior University	Cpg conjugates and methods of use
WO2025031498A1 (zh) *	2023-08-10	2025-02-13	浙江海昶生物医药技术有限公司	Toll样受体激动剂及其应用

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4458066A (en)	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
US4948882A (en)	1983-02-22	1990-08-14	Syngene, Inc.	Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4650675A (en)	1983-08-18	1987-03-17	The Children's Medical Center Corporation	Oligonucleotide conjugates
US5118802A (en)	1983-12-20	1992-06-02	California Institute Of Technology	DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5015733A (en)	1983-12-20	1991-05-14	California Institute Of Technology	Nucleosides possessing blocked aliphatic amino groups
US4849513A (en)	1983-12-20	1989-07-18	California Institute Of Technology	Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US5118800A (en)	1983-12-20	1992-06-02	California Institute Of Technology	Oligonucleotides possessing a primary amino group in the terminal nucleotide
US4828991A (en)	1984-01-31	1989-05-09	Akzo N.V.	Tumor specific monoclonal antibodies
US5093232A (en)	1985-12-11	1992-03-03	Chiron Corporation	Nucleic acid probes
US4910300A (en)	1985-12-11	1990-03-20	Chiron Corporation	Method for making nucleic acid probes
US5124246A (en)	1987-10-15	1992-06-23	Chiron Corporation	Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5278302A (en)	1988-05-26	1994-01-11	University Patents, Inc.	Polynucleotide phosphorodithioates
US5391723A (en)	1989-05-31	1995-02-21	Neorx Corporation	Oligonucleotide conjugates
US5552391A (en)	1990-01-16	1996-09-03	La Jolla Pharmaceutical Company	Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5460831A (en)	1990-06-22	1995-10-24	The Regents Of The University Of California	Targeted transfection nanoparticles
JPH04352724A (ja) *	1990-07-27	1992-12-07	Mitsui Toatsu Chem Inc	免疫調節型治療剤
EP0468520A3 (en)	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
US5932214A (en)	1994-08-11	1999-08-03	Biogen, Inc.	Treatment for inflammatory bowel disease with VLA-4 blockers
US5849719A (en)	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
AU713040B2 (en)	1994-07-15	1999-11-18	University Of Iowa Research Foundation, The	Immunomodulatory oligonucleotides
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
CA2244946C (en)	1996-01-30	2010-04-13	The Regents Of The University Of California	Gene expression vectors which generate an antigen specific immune response and methods of using the same
DE19631919C2 (de)	1996-08-07	1998-07-16	Deutsches Krebsforsch	Anti-Sinn-RNA mit Sekundärstruktur
WO1998016247A1 (en)	1996-10-11	1998-04-23	The Regents Of The University Of California	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
CA2281838A1 (en)	1997-02-28	1998-09-03	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU753688B2 (en)	1997-03-10	2002-10-24	Ottawa Civic Loeb Research Institute	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en)	1997-04-30	2002-07-30	Hybridon, Inc.	Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
JP2001526688A (ja)	1997-05-19	2001-12-18	メルクエンドカンパニーインコーポレーテッド	オリゴヌクレオチドアジュバント
EP1003531B1 (de)	1997-05-20	2007-08-22	Ottawa Health Research Institute	Verfahren zur Herstellung von Nukleinsäurekonstrukten
WO1998055609A1 (en)	1997-06-06	1998-12-10	The Regents Of The University Of California	Inhibitors of dna immunostimulatory sequence activity
US20040006034A1 (en) *	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6589940B1 (en) *	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6157654A (en) *	1997-06-24	2000-12-05	Alcatel Networks Corporation	Adaptive service weight assignments for ATM scheduling
PT1009413E (pt)	1997-09-05	2007-05-31	Univ California	Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
GB9727262D0 (en)	1997-12-24	1998-02-25	Smithkline Beecham Biolog	Vaccine
JPH11209289A (ja)	1998-01-22	1999-08-03	Taisho Pharmaceut Co Ltd	粘膜免疫誘起剤
US6218371B1 (en)	1998-04-03	2001-04-17	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP1077708A1 (de)	1998-05-06	2001-02-28	University Of Iowa Research Foundation	Methoden zur preventiven und therapeutischen behandlung von parasitären infektionen und damit verbundener krankheiten mittels cpg oligonukleotiden
DK1077722T3 (da)	1998-05-22	2006-11-27	Ottawa Health Research Inst	Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6562798B1 (en) *	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
JP2002521489A (ja)	1998-07-27	2002-07-16	ユニバーシティオブアイオワリサーチファウンデーション	ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法
JP2002524473A (ja) *	1998-09-09	2002-08-06	ジエンザイムコーポレイション	プラスミドベクターのメチル化
US20020065236A1 (en) *	1998-09-09	2002-05-30	Yew Nelson S.	CpG reduced plasmids and viral vectors
JP2003524602A (ja)	1998-09-18	2003-08-19	ダイナバックステクノロジーズコーポレイション	ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
CA2344558A1 (en)	1998-10-09	2000-04-20	Dynavax Technologies Corporation	Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
US6424622B1 (en) *	1999-02-12	2002-07-23	Nec Usa, Inc.	Optimal buffer management scheme with dynamic queue length thresholds for ATM switches
US6647011B1 (en) *	1999-02-22	2003-11-11	Marconi Communications, Inc.	Method and system for switching using an arbitrator
WO2000054803A2 (en)	1999-03-16	2000-09-21	Panacea Pharmaceuticals, Llc	Immunostimulatory nucleic acids and antigens
US6628668B1 (en) *	1999-03-16	2003-09-30	Fujitsu Network Communications, Inc.	Crosspoint switch bandwidth allocation management
EP1176966B1 (de)	1999-04-12	2013-04-03	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Oligodeoxynukleotide und deren verwendung zur induktion einer immunreaktion
EP1177439B1 (de)	1999-04-29	2004-09-08	Coley Pharmaceutical GmbH	Screening nach modulatoren der funktion von immunstimulatorischer dna
AP1891A (en)	1999-05-06	2008-09-23	The Immune Response Corp	HIV immunogenic compositions and methods.
DE60017259T2 (de)	1999-08-13	2005-12-08	Hybridon, Inc., Cambridge	Modulation der CPG-Oligonukleotid-vermittelten Immunstimulation durch Positionsbedingte Modifikation von Nukleosiden
US7479285B1 (en) *	1999-08-19	2009-01-20	Dynavax Technologies Corporation	Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
AU780535B2 (en)	1999-08-27	2005-03-24	Inex Pharmaceuticals Corp.	Compositions for stimulating cytokine secretion and inducing an immune response
US6165726A (en)	1999-09-21	2000-12-26	Ut-Battelle, Llc	Non-radioactive methods for chemical cleavage sequencing and footprinting of nucleic acids
WO2001022972A2 (en) *	1999-09-25	2001-04-05	University Of Iowa Research Foundation	Immunostimulatory nucleic acids
IL148844A0 (en)	1999-09-27	2002-09-12	Coley Pharm Group Inc	Methods related to immunostimulatory nucleic acid-induced interferon
US7223398B1 (en)	1999-11-15	2007-05-29	Dynavax Technologies Corporation	Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
WO2001045750A1 (en)	1999-12-21	2001-06-28	The Regents Of The University Of California	Method for preventing an anaphylactic reaction
WO2001051500A1 (en)	2000-01-14	2001-07-19	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
WO2001055370A2 (en)	2000-01-26	2001-08-02	Hybridon, Inc.	MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
AT409085B (de)	2000-01-28	2002-05-27	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US6552006B2 (en) *	2000-01-31	2003-04-22	The Regents Of The University Of California	Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
CA2399550A1 (en) *	2000-02-23	2001-08-30	The Regents Of The University Of California	Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20030129251A1 (en)	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
US20020107212A1 (en)	2000-03-10	2002-08-08	Nest Gary Van	Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20020098199A1 (en)	2000-03-10	2002-07-25	Gary Van Nest	Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20020028784A1 (en)	2000-03-10	2002-03-07	Nest Gary Van	Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US7157437B2 (en)	2000-03-10	2007-01-02	Dynavax Technologies Corporation	Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en)	2000-03-10	2001-11-29	Gary Van Nest	Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US7129222B2 (en) *	2000-03-10	2006-10-31	Dynavax Technologies Corporation	Immunomodulatory formulations and methods for use thereof
CA2404041A1 (en)	2000-03-28	2001-10-04	The Regents Of The University Of California	Methods for increasing a cytotoxic t lymphocyte response in vivo
US20020142978A1 (en)	2000-04-07	2002-10-03	Eyal Raz	Synergistic improvements to polynucleotide vaccines
AU2001257366B2 (en)	2000-05-01	2006-03-16	Idera Pharmaceuticals, Inc.	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
EP1292331A2 (de)	2000-06-07	2003-03-19	Biosynexus Incorporated	Immunstimulierende rns/dns hybridmolekule
WO2002018631A2 (de)	2000-09-01	2002-03-07	Epigenomics Ag	Diagnose von bestehenden erkrankungen oder der prädisposition für bestimmte erkrankungen
EP2292632A3 (de)	2000-09-26	2012-07-25	Idera Pharmaceuticals, Inc.	Modulation der immunostimulatorischen Aktivität von immunostimulierenden Oligonukleotidanaloga durch positionelle chemische Veränderungen
KR100343935B1 (ko) *	2000-10-09	2002-07-20	주식회사 하이닉스반도체	Ｉｍｔ-2000 시스템내 ａｔｍ 교환기에서의 ｄｂｗｒｒ 셀스케줄링 장치 및 방법
WO2002069369A2 (en)	2000-12-08	2002-09-06	Coley Pharmaceutical Gmbh	Cpg-like nucleic acids and methods of use thereof
US6882625B2 (en) *	2000-12-14	2005-04-19	Nokia Networks Oy	Method for scheduling packetized data traffic
EP1364010B1 (de) *	2000-12-27	2010-06-16	Dynavax Technologies Corporation	Immunomodulatorische polynukleotide und verfahren zur deren verwendung
WO2002074922A2 (en)	2001-03-16	2002-09-26	The Regents Of The University Of California	Compositions and methods for modulating an immune response
US7176296B2 (en) *	2001-04-30	2007-02-13	Idera Pharmaceuticals, Inc.	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7105495B2 (en) *	2001-04-30	2006-09-12	Idera Pharmaceuticals, Inc.	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US20040132677A1 (en) *	2001-06-21	2004-07-08	Fearon Karen L.	Chimeric immunomodulatory compounds and methods of using the same-IV
KR100985457B1 (ko) *	2001-06-21	2010-10-06	다이나박스 테크놀로지 코퍼레이션	키메라 면역조절 화합물 및 그것들의 사용 방법
US7785610B2 (en) *	2001-06-21	2010-08-31	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same—III
AU2002326561B2 (en) *	2001-08-07	2008-04-03	Dynavax Technologies Corporation	Immunomodulatory compositions, formulations, and methods for use thereof
EA007232B1 (ru) *	2001-08-17	2006-08-25	Коли Фармасьютикал Гмбх	Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
CN101160399A (zh) *	2002-04-22	2008-04-09	拜奥尼茨生命科学公司	寡核苷酸组合物及其在调节免疫应答中的应用
US7884083B2 (en)	2002-08-12	2011-02-08	Dynavax Technologies Corporation	Immunomodulatory compositions, methods of making, and methods of use thereof
DK1992635T3 (da)	2002-12-23	2012-03-05	Dynavax Tech Corp	Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
WO2008073661A2 (en) *	2006-11-09	2008-06-19	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides

2003
- 2003-12-18 DK DK08013086.7T patent/DK1992635T3/da active
- 2003-12-18 CN CNB2003801073014A patent/CN100546998C/zh not_active Expired - Lifetime
- 2003-12-18 ES ES08013086T patent/ES2381309T3/es not_active Expired - Lifetime
- 2003-12-18 NZ NZ541027A patent/NZ541027A/en not_active IP Right Cessation
- 2003-12-18 JP JP2005510051A patent/JP5102959B2/ja not_active Expired - Lifetime
- 2003-12-18 CA CA2511475A patent/CA2511475C/en not_active Expired - Lifetime
- 2003-12-18 PT PT08013086T patent/PT1992635E/pt unknown
- 2003-12-18 DE DE60329223T patent/DE60329223D1/de not_active Expired - Lifetime
- 2003-12-18 KR KR1020127008544A patent/KR101309501B1/ko not_active Expired - Lifetime
- 2003-12-18 SG SG2011035342A patent/SG2011035342A/en unknown
- 2003-12-18 EP EP08013086A patent/EP1992635B1/de not_active Expired - Lifetime
- 2003-12-18 SI SI200331695T patent/SI1575977T1/sl unknown
- 2003-12-18 ES ES03814325T patent/ES2328807T3/es not_active Expired - Lifetime
- 2003-12-18 SG SG2007045727A patent/SG173219A1/en unknown
- 2003-12-18 PT PT03814325T patent/PT1575977E/pt unknown
- 2003-12-18 EP EP03814325A patent/EP1575977B1/de not_active Expired - Lifetime
- 2003-12-18 AU AU2003297483A patent/AU2003297483B2/en not_active Expired
- 2003-12-18 AT AT08013086T patent/ATE544772T1/de active
- 2003-12-18 WO PCT/US2003/041001 patent/WO2004058179A2/en not_active Ceased
- 2003-12-18 KR KR1020127025824A patent/KR20120128729A/ko not_active Ceased
- 2003-12-18 DK DK03814325T patent/DK1575977T3/da active
- 2003-12-18 KR KR1020057011912A patent/KR101178816B1/ko not_active Expired - Lifetime
- 2003-12-18 AT AT03814325T patent/ATE442376T1/de active
- 2003-12-18 CN CN2009101704063A patent/CN101693890B/zh not_active Expired - Lifetime
- 2003-12-18 US US10/741,720 patent/US7745606B2/en not_active Expired - Lifetime
2009
- 2009-11-25 CY CY20091101221T patent/CY1109642T1/el unknown
2011
- 2011-12-16 JP JP2011276052A patent/JP2012070757A/ja active Pending
2012
- 2012-04-25 CY CY20121100394T patent/CY1112704T1/el unknown

Also Published As

Publication number	Publication date
PT1575977E (pt)	2009-12-15
ATE544772T1 (de)	2012-02-15
PT1992635E (pt)	2012-03-20
NZ541027A (en)	2008-04-30
EP1575977A4 (de)	2006-04-26
CA2511475C (en)	2013-11-19
ES2381309T3 (es)	2012-05-25
KR20050089983A (ko)	2005-09-09
DE60329223D1 (de)	2009-10-22
EP1575977A2 (de)	2005-09-21
JP2006512096A (ja)	2006-04-13
CN101693890A (zh)	2010-04-14
CN100546998C (zh)	2009-10-07
CY1112704T1 (el)	2016-02-10
JP5102959B2 (ja)	2012-12-19
AU2003297483A1 (en)	2004-07-22
AU2003297483B2 (en)	2010-11-18
DK1575977T3 (da)	2009-11-09
KR20120046326A (ko)	2012-05-09
HK1125943A1 (en)	2009-08-21
US20060058254A1 (en)	2006-03-16
ES2328807T3 (es)	2009-11-18
WO2004058179A2 (en)	2004-07-15
EP1575977B1 (de)	2009-09-09
JP2012070757A (ja)	2012-04-12
CA2511475A1 (en)	2004-07-15
EP1992635A1 (de)	2008-11-19
EP1992635B1 (de)	2012-02-08
SG2011035342A (en)	2016-12-29
SG173219A1 (en)	2011-08-29
CN1745089A (zh)	2006-03-08
CN101693890B (zh)	2012-09-05
KR20120128729A (ko)	2012-11-27
CY1109642T1 (el)	2014-08-13
WO2004058179A3 (en)	2004-11-11
SI1575977T1 (sl)	2010-01-29
KR101309501B1 (ko)	2013-09-24
DK1992635T3 (da)	2012-03-05
KR101178816B1 (ko)	2012-09-07
US7745606B2 (en)	2010-06-29

Legal Events

Date

Code

Title

Description

2010-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1575977

Country of ref document: EP

Publication	Publication Date	Title
DE60329223D1 (de)	2009-10-22	Oligonukleotide mit einer immunsystemstimulierenden sequenz und verfahren zu deren anwendung
ATE471374T1 (de)	2010-07-15	Immunomodulatorische polynukleotide und verfahren zur deren verwendung
DE60335010D1 (de)	2010-12-30	Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
DE60223757D1 (de)	2008-01-10	Buchbindevorrichtung und Verfahren
DE60210847D1 (de)	2006-06-01	Verfahren und Vorrichtung zur Erzeugung von verteilten digitalen Unterschriften
DE60222864D1 (de)	2007-11-22	Verfahren und vorrichtung zur untersuchung von fluiden
EP1272768A4 (de)	2005-09-07	Mikrofluidische einrichtungen und verfahren
DE60237184D1 (de)	2010-09-16	Verfahren zur Erzeugung von Bewegungen
DE60206472D1 (de)	2006-02-16	Verfahren und vorrichtung zur herstellung von mineralwolle
DE602004013122D1 (de)	2008-05-29	Verfahren zur optimierung einer reihenfolge der komponentenanbringung, vorrichtung damit und anbringvorrichtung
DE60217597D1 (de)	2007-03-08	Gerät und Verfahren zur Personenerkennung
DE60226674D1 (de)	2008-07-03	Verfahren und Vorrichtung zur Ausrüstung von Bohrlöchern
DE60121066D1 (de)	2006-08-03	Angriffsresistente kryptographische Verfahren und Vorrichtung
DE602004012364D1 (de)	2008-04-24	Zielführungsvorrichtung, System und Verfahren
DE60207863D1 (de)	2006-01-12	Vorrichtung und Verfahren zur Gesichtserkennung
DE60031349D1 (de)	2006-11-30	Verfahren und Vorrichtung zur Erzeugung von Fluoreszenzbildern
DE60222464D1 (de)	2007-10-25	Treibriemen und Verfahren
ATE302494T1 (de)	2005-09-15	Einrichtung und verfahren zur erzeugung elektrischer energie
EP1379535A4 (de)	2006-11-15	Zur hervorrufung einer verbesserten immunantwort fähige expressionsvektoren und verfahren zu deren verwendung
ATE338619T1 (de)	2006-09-15	Verfahren und vorrichtung zur herstellung von borsten
EP1483385A4 (de)	2005-08-24	Zusammensetzungen und verfahren zur erzeugung einer immunantwort
DE60120945D1 (de)	2006-08-03	System und Verfahren zum Bereitstellen von Dienstleistungen
DE60212248D1 (de)	2006-07-27	Informationssicherheitsvorrichtung, Vorrichtung und Verfahren zur Erzeugung einer Primzahl
DE60221018D1 (de)	2007-08-16	Verfahren und vorrichtung zur herstellung von kontaktlinsen
EP1406693A4 (de)	2007-06-06	Verfahren und vorrichtung zur applikation von strahlung